Publication of Annual Report and Financial Statements for the Year ended 31 December 2021

Acacia Pharma Group plc

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.

Cambridge, UK and Indianapolis, US – 29 April 2022, 23:00 CEST: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces the publication of its Annual Report and Financial Statements for the Year ended 31 December 2021.

The Annual Report is attached below and also available on www.acaciapharma.com in the Investors/Financial Reports and Presentations section.

Contacts

Acacia Pharma Group plc Mike Bolinder, CEO +44 1223 919760 / +1 317 505 1280 IR@acaciapharma.com	International Media Frazer Hall, Mark Swallow, David Dible MEDiSTRAVA Consulting +44 20 3928 6900 acaciapharma@medistrava.com
US Investors LifeSci Advisors Irina Koffler +1 917-734-7387 ikoffler@lifesciadvisors.com	Media in Belgium and the Netherlands Chris Van Raemdonck +32 499 58 55 31 chrisvanraemdonck@telenet.be

Attachment

• Acacia Pharma Annual Report 2021